Skip to main content
. Author manuscript; available in PMC: 2014 Mar 26.
Published in final edited form as: Cancer. 2012 Jul 18;119(2):356–362. doi: 10.1002/cncr.27730

Table 2.

Summary of treatment history by genotype

p-values
Treatment KRAS (+) (n=241) EGFR (+) (n=275) KRAS/EGFR wild-type (WT) (n=520) EGFR(+)vs. EGFR KRAS (+)WT vs. KRAS WT
Platinum
Yes 152 (63%) 132 (48%) 327 (63%) 0.13
unknown 25 (10%) 29 (11%) 57 (11%)

Bevacizumab
Yes 88 (37%) 65 (23%) 190 (37%) 0.26
Unknown 27 (11%) 39 (14%) 64 (12%)

EGFR-TKI
Yes 44 (18%) 233 (85%) 148 (28%) <0.001
Unknown 28 (12%) 34 (12%) 84 (16%)